Activated charcoal
- Generic Name
- Activated charcoal
- Brand Names
- Actidose, Insta-char
- Drug Type
- Small Molecule
- Chemical Formula
- C
- CAS Number
- 64365-11-3
- Unique Ingredient Identifier
- 2P3VWU3H10
- Background
Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity for various substances. It is used as a...
- Indication
Used as a antidote to treat poisonings following excessive oral ingestion of certain medications or poisons.
- Associated Conditions
- Abdominal Cramping, Aerophagy, Bloating, Constipation, Delayed Transit Time, Flatulence, Belching, Meteorism
- Associated Therapies
- -
The Effect of Probiotics vs Activated Charcoal in the Management of CKD Patients Suffering From Uremic Pruritus.
- Conditions
- Interventions
- First Posted Date
- 2024-08-30
- Last Posted Date
- 2024-08-30
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 123
- Registration Number
- NCT06579066
Does a Soft Drink Mixture Improve Tolerance of Activated Charcoal in the Adult Poisoned Patient Without Affecting Efficacy
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-05-30
- Target Recruit Count
- 5
- Registration Number
- NCT06219967
- Locations
- 🇺🇸
SUNY Upstate Medical University Clinical Research Unit, Syracuse, New York, United States
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
- First Posted Date
- 2023-11-21
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1400
- Registration Number
- NCT06141473
- Locations
- 🇺🇸
University of Alabama at Birmingham- Site Number : 8401135, Birmingham, Alabama, United States
🇺🇸North Central Neurology Associates- Site Number : 8401100, Cullman, Alabama, United States
🇺🇸St. Joseph's Hospital and Medical Center- Site Number : 8401139, Phoenix, Arizona, United States
Evaluation of Protective Effect of Activated Charcoal and Probiotic Against Progression of Chronic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2022-09-14
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Waleed Khaild Rahman Kareem Al-kabi
- Target Recruit Count
- 60
- Registration Number
- NCT05540431
- Locations
- 🇮🇶
Waleed Khaild Rahman Alkabi, Al-diwanyia, Iraq
Activated CHARcoal in Poisoned Patient - Pilot Trial
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Laval University
- Target Recruit Count
- 100
- Registration Number
- NCT05471479
- Locations
- 🇨🇦
CHU de Québec - Université Laval, Québec, Canada
Charcoal in Lung Cancer Patients Undergoing TEMLA
- First Posted Date
- 2021-06-16
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Registration Number
- NCT04928950
Non Inferiority Study of a Reduced Dose of Activated Charcoal on Rivaroxaban Pharmacokinetics.
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2022-12-05
- Target Recruit Count
- 12
- Registration Number
- NCT04767776
- Locations
- 🇫🇷
CHU de SAINT-ETIENNE, Saint-etienne, France
Role of Activated Charcoal in Decreasing Blood Urea, Creatinine and Phosphorous
- Conditions
- Interventions
- First Posted Date
- 2020-03-17
- Last Posted Date
- 2020-05-14
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 90
- Registration Number
- NCT04311645
Activates Charcoal for Patients Undergoing Invasive Procedure Delayed Due to Direct Oral Anticoagulants
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2017-06-09
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 140
- Registration Number
- NCT02969746
- Locations
- 🇫🇷
CH Le MANS, Le Mans, France
🇫🇷CHU Clermont-ferrand, Cleron, France
🇫🇷CHU de Poitiers, Poitiers, France
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 22
- Registration Number
- NCT02691325
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.